JP2022542524A5 - - Google Patents
Info
- Publication number
- JP2022542524A5 JP2022542524A5 JP2022506809A JP2022506809A JP2022542524A5 JP 2022542524 A5 JP2022542524 A5 JP 2022542524A5 JP 2022506809 A JP2022506809 A JP 2022506809A JP 2022506809 A JP2022506809 A JP 2022506809A JP 2022542524 A5 JP2022542524 A5 JP 2022542524A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic composition
- composition according
- antibody
- tumor
- cell receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882353P | 2019-08-02 | 2019-08-02 | |
| US62/882,353 | 2019-08-02 | ||
| US202063047693P | 2020-07-02 | 2020-07-02 | |
| US63/047,693 | 2020-07-02 | ||
| PCT/US2020/044616 WO2021026028A1 (en) | 2019-08-02 | 2020-07-31 | Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022542524A JP2022542524A (ja) | 2022-10-04 |
| JP2022542524A5 true JP2022542524A5 (https=) | 2023-08-29 |
Family
ID=72193578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506809A Pending JP2022542524A (ja) | 2019-08-02 | 2020-07-31 | 抗ｃｃｒ５受容体薬剤の投与を含むがんを処置または予防する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220298249A1 (https=) |
| EP (1) | EP4007603A1 (https=) |
| JP (1) | JP2022542524A (https=) |
| CN (1) | CN114502594A (https=) |
| AU (1) | AU2020324948A1 (https=) |
| BR (1) | BR112022001037A2 (https=) |
| CA (1) | CA3146474A1 (https=) |
| MX (1) | MX2022001411A (https=) |
| WO (1) | WO2021026028A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023532019A (ja) * | 2020-06-23 | 2023-07-26 | マドン アドバイザーズ エルエルシー | 抗ｃｃｒ５モノクローナル抗体ベースの組成物および方法 |
| WO2025250666A1 (en) * | 2024-05-29 | 2025-12-04 | Cytodyn, Inc. | Methods of treating cancer and inflammation-related diseases with leronlimab |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| CA2616189C (en) | 2005-07-22 | 2019-03-26 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| MX2008014296A (es) * | 2006-06-12 | 2009-03-06 | Pfizer Prod Inc | Antagonista de ccr5 para mejorar la restitucion inmunitaria y tratar la infeccion oportunista en pacientes con vih. |
| CA2939464A1 (en) * | 2014-02-18 | 2015-08-27 | Cytodyn Inc. | Use of anti-ccr5 antibodies in graft versus host disease |
| CN107847514A (zh) | 2015-06-23 | 2018-03-27 | 西托戴恩股份有限公司 | 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变 |
| US20190016810A1 (en) * | 2017-05-11 | 2019-01-17 | Cytodyn Inc. | Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents |
-
2020
- 2020-07-31 CA CA3146474A patent/CA3146474A1/en active Pending
- 2020-07-31 EP EP20760991.8A patent/EP4007603A1/en active Pending
- 2020-07-31 MX MX2022001411A patent/MX2022001411A/es unknown
- 2020-07-31 US US17/631,161 patent/US20220298249A1/en active Pending
- 2020-07-31 JP JP2022506809A patent/JP2022542524A/ja active Pending
- 2020-07-31 BR BR112022001037A patent/BR112022001037A2/pt unknown
- 2020-07-31 CN CN202080069162.4A patent/CN114502594A/zh active Pending
- 2020-07-31 AU AU2020324948A patent/AU2020324948A1/en active Pending
- 2020-07-31 WO PCT/US2020/044616 patent/WO2021026028A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heo et al. | Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer | |
| Cruz-Burgos et al. | New approaches in oncology for repositioning drugs: the case of PDE5 inhibitor sildenafil | |
| James et al. | A phase II study of the bispecific antibody MDX-H210 (anti-HER2× CD64) with GM-CSF in HER2+ advanced prostate cancer | |
| Orditura et al. | Treatment of gastric cancer | |
| Zhou et al. | Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination | |
| Ryan et al. | Randomized phase 3 trial of abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy | |
| JP2022542524A5 (https=) | ||
| Kang et al. | Down-regulation of TGF-β expression sensitizes the resistance of hepatocellular carcinoma cells to sorafenib | |
| JP2020537695A (ja) | ストレプトニグリンおよびラパマイシンを有効成分として含む、癌の予防または治療用薬学的組成物 | |
| CN115869413A (zh) | 一种药物组合物及其应用以及一种治疗前列腺癌的组合物及其应用 | |
| Lee et al. | Neoadjuvant hormonal therapy in carcinoma of the prostate | |
| JP2022519923A5 (https=) | ||
| Jung et al. | Unveiling the profound advantages of total neoadjuvant therapy in rectal cancer: A trailblazing exploration | |
| JP2014515393A (ja) | 腫瘍性疾患治療の組合せ医薬組成物 | |
| Niraula et al. | Broadening horizons in medical management of prostate cancer | |
| CN107349426B (zh) | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 | |
| JP2018520990A (ja) | 抗ｆｇｆｒ４抗体および胆汁酸捕捉剤の組み合わせ | |
| JP2023511277A5 (https=) | ||
| McLean et al. | Pediatric genitourinary tumors | |
| CN114272248B (zh) | 一种化疗免疫凝胶及其制备方法与应用 | |
| CN121668324A (zh) | Cgrp抑制剂瑞美吉泮与pd-1抑制剂在制备治疗结直肠癌肝转移药物中的应用 | |
| JP2025502955A (ja) | 抗体内包金属フラーレン複合体及びその使用 | |
| Cruz-Burgos et al. | Cruz-Herná ndez CD, Corté s-Ramı́rez SA, Camacho-Arroyo I, Gonzalez-Covarrubias V, Morales-Pacheco M, Trujillo-Bornios SI and Rodrı́guez-Dorantes M (2021) New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. Front | |
| Horinouchi et al. | MO31-2 Telisotuzumab vedotin monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer | |
| CN107137403B (zh) | 一种pi3k/mtor抑制剂在制备治疗胰腺癌的药物中的用途 |